Neolys Diagnostics is a Biotechnology company specialized in precision medicine for radiation oncology, Neolys Diagnostics develops innovative medical tests combining DNA repair biomarkers and radiotherapy treatment parameters to anticipate and reduce treatment-related side effects, optimize therapeutic efficacy, and contribute to healthcare cost reduction through personalized radiotherapy strategies.
Dr. Pereira, Sandrine is the Scientific Director of Neolys Diagnostics. With over 15 years of experience in radiosensitivity testing and oncology innovation, Sandrine Pereira leads Work Package 8 (WP8) within the TETRIS Project, ensuring scientific coherence between functional biomarkers, genetic data, and clinical application. Her Team members are Mathilde Hà-Lasnon and Laura Desrivot.
Neolys Diagnostics – WP8 Leadership: Cellular Sensitivity Testing in the TETRIS Prospective Cohort.
WP8 focuses on the assessment of cellular radiosensitivity and the integration of functional biomarkers with genetic information, including Polygenic Risk Scores (PRS) derived from SNP analysis, enabling multidimensional patient risk profiling. RadioDTect© and RadioProfile© Assays are Functional radiosensitivity testing assays. The RadioDTect© blood test and RadioProfile© skin test are performed on biological samples collected using standardized protocols from patients enrolled in the TETRIS prospective cohort (WP9).
Neolys Diagnostics is also part of WP4-Integration of functional and genomic data and WP7- Biological input for Digital Twin development. WP9 – Prospective collection and WP10 – Dissemination and Exploitation.
